Skip to main content
ConductScienceScienceDex
NIH funding notice PAR-23-165

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)

Closed on January 7, 2025.

Posted
April 7, 2023
Close date
January 7, 2025
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $567,718 in first-year total cost, median $567,718.

Most frequent study sections

  1. Neural Basis of Psychopathology, Addictions and Sleep Disorders Study Section[NPAS]1

Most frequent institutions

  1. MCLEAN HOSPITAL1
Competing awards under PAR-23-165 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Imaging the Functional State of the D2high Receptor in drug induced dopamine supersensitivity in schizophrenia1R01MH134074-01A1SUBBURAJU, SIVANMCLEAN HOSPITAL, MA$567,718NPAS

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
PAR-23-165: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) | ScienceDex | ConductScience